Literature DB >> 16879891

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

Joseph F Perz1, Gregory L Armstrong, Leigh A Farrington, Yvan J F Hutin, Beth P Bell.   

Abstract

BACKGROUND/AIMS: End-stage liver disease accounts for one in forty deaths worldwide. Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.
METHODS: The prevalence of serologic markers of HBV and HCV infections among patients diagnosed with cirrhosis or hepatocellular carcinoma (HCC) was obtained from representative samples of published reports. Attributable fractions of cirrhosis and HCC due to these infections were estimated for 11 WHO-based regions.
RESULTS: Globally, 57% of cirrhosis was attributable to either HBV (30%) or HCV (27%) and 78% of HCC was attributable to HBV (53%) or HCV (25%). Regionally, these infections usually accounted for >50% of HCC and cirrhosis. Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).
CONCLUSIONS: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.

Entities:  

Mesh:

Year:  2006        PMID: 16879891     DOI: 10.1016/j.jhep.2006.05.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  834 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Simultaneously high prevalences of hepatitis B and C virus infections in a population in Putian County, China.

Authors:  Wen-Ping Lu; Guo-Xian Lin; Shuang Shi; Jia-Hong Dong
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

3.  Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009.

Authors:  Stephanie C Melkonian; Melissa A Jim; Brigg Reilley; Jennifer Erdrich; Zahava Berkowitz; Charles L Wiggins; Donald Haverkamp; Mary C White
Journal:  Cancer Causes Control       Date:  2018-07-20       Impact factor: 2.506

4.  Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM.

Authors:  Long Sheng; Maoming Xiong; Cong Li; Xiangling Meng
Journal:  Pathol Oncol Res       Date:  2013-12-11       Impact factor: 3.201

5.  Increased expression of S100A6 promotes cell proliferation and migration in human hepatocellular carcinoma.

Authors:  Ziqiang Li; Mei Tang; Bo Ling; Shiying Liu; Yu Zheng; Chunlai Nie; Zhu Yuan; Liangxue Zhou; Gang Guo; Aiping Tong; Yuquan Wei
Journal:  J Mol Med (Berl)       Date:  2013-11-27       Impact factor: 4.599

Review 6.  Targeting the HGF/c-MET pathway in hepatocellular carcinoma.

Authors:  Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Journal:  Clin Cancer Res       Date:  2013-02-06       Impact factor: 12.531

7.  Dual-time points (18)F-FDG PET/CT imaging in detection of bone metastases from hepatocellular carcinoma.

Authors:  Xueren Zhao; Alex Yi; George Ariza; Lee Salcido
Journal:  Int J Clin Exp Med       Date:  2013-01-26

8.  Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.

Authors:  Zongtang Sun; Taoyang Chen; Snorri S Thorgeirsson; Qimin Zhan; Jianguo Chen; Ju-Hyun Park; Peixin Lu; Chu Chieh Hsia; Nengjin Wang; Libin Xu; Lingling Lu; Fei Huang; Yuanrong Zhu; Jianhua Lu; Zhengping Ni; Qinan Zhang; Yuying Wu; Guoting Liu; Zhiyuan Wu; Chunfeng Qu; Mitchell H Gail
Journal:  Carcinogenesis       Date:  2013-01-14       Impact factor: 4.944

9.  Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.

Authors:  Hui Xue; Meng Zhang; Jack Xq Pang; Fei Yan; Ying-Chao Li; Liang-Shan Lv; Jia Yuan; Muna Palikhe; Wei-Zhi Li; Zhi-Lun Wang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

10.  Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection.

Authors:  Feyza Gunduz; Chaithanya Mallikarjun; Luis A Balart; Srikanta Dash
Journal:  Exp Mol Pathol       Date:  2013-11-08       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.